Scarica l'app Stockscreener
84.50
0.43%
-0.395
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$84.90
Aprire:
$85.89
Volume 24 ore:
9.19M
Relative Volume:
0.78
Capitalizzazione di mercato:
$147.24B
Reddito:
$45.13B
Utile/perdita netta:
$6.28B
Rapporto P/E:
23.54
EPS:
3.5895
Flusso di cassa netto:
$7.38B
1 W Prestazione:
+0.26%
1M Prestazione:
-16.76%
6M Prestazione:
-35.26%
1 anno Prestazione:
-36.60%
Intervallo 1D:
$84.13
$86.47
Intervallo di 1 settimana:
$81.97
$86.47
Portata 52W:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
84.53 | 146.02B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.88 | 115.81B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
76.36 | 97.84B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
52.67 | 78.87B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
81.39 | 46.86B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Is Abbott’s Exact Sciences Deal And Nutrition Pivot Altering The Investment Case For Abbott (ABT)? - Yahoo Finance
Abbott Laboratories stock (US0028241000): Q1 beat, Exact Sciences deal and legal risks keep investor - AD HOC NEWS
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up - Yahoo Finance
Exact Sciences Deal and Legal Pressures Might Change The Case For Investing In Abbott (ABT) - simplywall.st
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Exact Sciences Corp. stock (US30063P1057): Acquired by Abbott for $20.6B - AD HOC NEWS
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment - Insider Monkey
Abbott class action alleges FreeStyle Libre 2 glucose monitor is defective - Class Action Lawsuits
Abbott Laboratories stock (US0028241000): shares rebound after earnings and guidance update - AD HOC NEWS
Insider trades: Okta and Abbott see buys, Micron insiders sell - MSN
How The Investment Narrative For Abbott Laboratories (ABT) Is Shifting With Recent Analyst Resets - Yahoo Finance
Nvision secures $55 million, with backing from Abbott - BioWorld News
Abbott Eterna Lawsuit Alleges Spinal Cord Stimulator Malfunction Resulted in Worsening Pain - AboutLawsuits.com
Abbott Laboratories stock (US0028241000): Q4 earnings call set for Jan. 22 - AD HOC NEWS
Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold? - Yahoo Finance
Abbott Securities Lawsuit Deepens Infant Formula Risks For Shareholders - simplywall.st
Abbott India Limited Issues Postal Ballot Notice for Appointment of Mr. James Wenner and Mr. Neeraj Jain to Its Board - scanx.trade
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Q1 2026 earnings beat sends Abbott stock higher by 3.04% - Traders Union
Abbott’s dividend yield near decade peak as investors weigh litigation costs By Investing.com - Investing.com Nigeria
Abbott’s dividend yield near decade peak, signaling rare buying opportunity - Investing.com
Abbott Laboratories stock (US0028241000): Q1 earnings beat with $11.16B revenue - AD HOC NEWS
ABT Stock Price, Quote & Chart | ABBOTT LABORATORIES (NYSE:ABT) - ChartMill
Could Cash Machine Abbott Laboratories Stock Be Your Next Buy? - Trefis
Operating margin % of Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged – TSX:ABT - TradingView
Jim Cramer says today’s market is punishing stocks harder than 1999 - CNBC
Abbott Laboratories Shs UnSponsored Canadian Depository Receipt Hedged Statistics – TSX:ABT - TradingView
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
ABT Stock Quote Price and Forecast - CNN
Why is Abbott Laboratories stock down today? - Traders Union
Abbott Stock Down 38% in 2026: Does the $23 Billion Exact Sciences Acquisition Change the Math? - TIKR.com
Abbott Laboratories trades at decade low with growth and dividend streak, poised for EPS boost by 2028-29. - Pluang
Abbott: Three Supercycles, Mispriced At A 10-Year Low - Seeking Alpha
Abbott Laboratories stock (US0028241000): Q1 earnings beat estimates with $11.16B revenue - AD HOC NEWS
Abbott Laboratories stock (US0028241000): Kepler Cheuvreux Suisse buys new stake - AD HOC NEWS
Wearable Skin Patch Market Size Propelled by 12.8% CAGR | - openPR.com
Implantable Medical Devices Market Is Going to Boom | Medtronic, Abbott Laboratories - openPR.com
Helicobacter Pylori Testing Market Is Going to Boom | Abbott Laboratories, Roche Diagnostics, Siemens Healthineers - openPR.com
Lateral Flow Assay Component Market Is Going to Boom | Abbott Laboratories, BD - openPR.com
Abbott Laboratories (ABT) Stock Analysis: Strong Buy Ratings Signal Potential 40.7% Upside - DirectorsTalk Interviews
A Look At Abbott Laboratories (ABT) Valuation After Mixed Q1 Results And Baby Formula Legal Ruling - Yahoo Finance
Is It Time To Reconsider Abbott Laboratories (ABT) After The Recent Share Price Slump? - simplywall.st
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott Laboratories Hires PhronesisDC on Tax Policy - Legis1
Abbott Laboratories Is On Sale, Don't Overlook It - Seeking Alpha
Abbott Laboratories: Mispriced Growth Behind Near-Term Noise? - TradingView
Abbott Laboratories stock (US0028241000): Shares hit 52-week low amid sector weakness and valuation - AD HOC NEWS
Abbott ends six-session losing streak - MSN
Pay Less, Gain More: RMD, MDT Top Abbott Laboratories Stock - Trefis
Abbott Laboratories Stock (ABT) Closed Down by 3.22% on May 8: A Full Analysis - TradingKey
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):